Completed PHASE3 INTERVENTIONAL 2-arm NCT00382031

Zalutumumab in Patients With Non-curable Head and Neck Cancer

An Open-Labeled Randomized Parallel Group Trial of Zalutumumab, a Human Monoclonal Anti-EGFr Antibody, in Combination With Best Supportive Care (BSC) vs BSC, in Pts With Non-Curable SCCHN Who Have Failed Standard Platinum-Based Chemotherapy

Sponsor: Genmab

Conditions Head and Neck Cancer Squamous Cell Cancer

Interventions Control Zalutumumab

Updated 9 times since 2017 Last updated: Aug 9, 2013 Started: Nov 30, 2006 Primary completion: Dec 31, 2009 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00382031, this PHASE3 trial focuses on Head and Neck Cancer and Squamous Cell Cancer and remains completed. Sponsored by Genmab, it has been updated 9 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genmab

Data source: Genmab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antwerp, Belgium , Belgorod, Russia , Belgrade, Serbia , Belo Horizonte, Brazil , Bielsko-Biala, Poland , Bristol, United Kingdom , Brussels, Belgium , Budapest, Hungary , Calgary, Canada , Charleroi, Belgium and 60 more locations